LYEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lyell Immunopharma Inc (LYEL) is not a strong buy at the moment for a beginner investor with a long-term focus. While the technical indicators show some bullish momentum, the company's financial performance is weak, with significant declines in revenue, net income, and EPS. Additionally, there are no recent positive news catalysts or significant trading trends to support immediate investment. Analysts have a positive outlook with high price targets, but the lack of strong proprietary trading signals and the absence of recent congress or influential trading data suggest a cautious approach. Holding off for now is recommended.
The MACD is positive at 0.444, indicating bullish momentum, but it is contracting. RSI is neutral at 59.639. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are R1: 24.751 and R2: 26.042, while support levels are S1: 20.572 and S2: 19.281.
and a positive outlook on the company's lead product, ronde-cel, in the CAR-T therapy space. The stock has bullish moving averages and a positive MACD.
The company's financial performance in Q4 2025 shows significant declines in revenue (-45.45% YoY), net income (-26.68% YoY), and EPS (-49.96% YoY). No recent news or significant trading trends from hedge funds, insiders, or congress. The stock has a low probability of significant short-term gains based on historical candlestick patterns.
In Q4 2025, revenue dropped by 45.45% YoY to 6000. Net income decreased by 26.68% YoY to -140,723,000, and EPS fell by 49.96% YoY to -6.86. Gross margin remained stable at 100%.
Analysts have a positive outlook with Buy and Outperform ratings. Price targets range from $34 to $44, with the potential for significant upside in a bull case scenario.
